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What is already known about this topic? 
• Prenatal genetic screens and diagnostic tests are a core component to the 
delivery of high-quality, evidence-based prenatal care. 
• It is critical that pregnant patients have the information and resources to make an 
informed decision about a growing array of prenatal genetic screening and 
diagnostic testing options.  
• In the decision-making process, pregnant patients weigh the risks and benefits of 
gaining genetic information about the fetus with the risks and benefits of the 
available screens and diagnostic tests.  
 
What does this study add?  
• The pandemic has led to significant changes in healthcare delivery and 
insurance benefits for prenatal genetic testing, raising key questions about how 
pregnant patient are weighing the risks and benefits of the available prenatal 
genetic screening and diagnostic testing options against the risks of COVID 
exposure by presenting to a healthcare facility for testing.  
 
• COVID-19 appears to impact how women view the utility of prenatal genetic 


















screening and diagnostic testing in addition to when in the pregnancy they may 
elect to undergo testing.  
 
 
• The COVID-19 pandemic has resulted in increased levels of concern and anxiety 
that may be encountered by pregnant women in the testing process, raising 
awareness of the need for additional resources to support patients’ decision-


































Objective: We conducted a study to examine the impact of COVID on patients’ access 
and utilization of prenatal genetic screens and diagnostic tests at the onset of the 
COVID-19 pandemic in the U.S.  
 
Methods:   We conducted telephone interviews with 40 patients to examine how the 
pandemic affected prenatal genetic screening and diagnostic testing decisions during 
the initial months of the pandemic in the U.S. An interview guide queried experiences 
with the ability to access information about prenatal genetic testing options and to utilize 
the tests when desired. Audio-recordings were transcribed and coded using NVivo 12. 
Analysis was conducted using Grounded Theory.  
 
Results:  The pandemic did not alter most participants' decisions to undergo prenatal 
genetic testing. Yet, it did impact how participants viewed the risks and benefits of 
testing and timing of testing. There was heightened anxiety among those who 
underwent testing, stemming from the risk of viral exposure and the fear of being alone 
if pregnancy loss or fetal abnormality was identified at the time of an ultrasound-based 



















Conclusion:  The pandemic may impact patients’ access and utilization of prenatal 
genetic tests. More research is needed to determine how best to meet pregnant 
patients’ decision-making needs during this time.  
 
INTRODUCTION 
Prenatal genetic screening tests and diagnostic tests (collectively referred to as prenatal 
genetic tests) are a core component of delivering high-quality, evidence-based prenatal 
care.1-4  This includes prenatal genetic screening tests performed by analyzing maternal 
serum or ultrasound and diagnostic tests performed by amniocentesis or chorionic villus 
sampling (CVS).2 Prenatal genetic tests are highly time-sensitive as delays can have 
significant implications for obstetric outcomes.5,6  Thus, it is critical to understand if and 
how the pandemic may affect patients’ ability to access prenatal genetic tests in an 
informed and timely fashion during this time.  
 
It is currently unknown if and how the COVID-19 pandemic may affect pregnant 
women’s decision-making about the use of prenatal genetic tests. A rapid and massive 
response to the virus took place across healthcare systems, with telehealth 
implementation as a core component of these changes to mitigate the risk of viral 
exposure among patients, healthcare providers, and communities.7 This approach 
helped maintain prenatal care delivery while avoiding the possible risks associated with 
an in-person visit, a strategy particularly relevant to pregnant patients because of the 


















Yet, in-person visits are required for those patients who elect for prenatal genetic 
testing. The decision to proceed with testing requires the patient to have a blood draw 
or ultrasound-based procedure. These processes entail presenting to a healthcare 
facility and breaking social distancing to be in close proximity to a clinician performing 
the procedure. How pregnant patients will consider the risks of COVID exposure in their 
decisions about if to undergo testing, what kind of test to use, and when to have testing 
performed are unknown. 
  
Given the potential effects of COVID-19 on maternal and neonatal outcomes and the 
importance of prenatal genetic testing for the delivery of high-quality prenatal care, we 
conducted a study to assess the pandemic's onset on women’s decision-making for 
prenatal genetic testing. This time frame is significant as it represents the rapid influx of 
new information, policies, and procedures about the virus and the pandemic. These 
data are critical to developing COVID-19 strategies for the delivery of prenatal care that 
reflect pregnant patients' decision-making needs as they navigate the fast-paced and 
novel changes associated with the pandemic.  
 
METHODS  
All research procedures were approved by the Institutional Review Board of the 
Cleveland Clinic Healthcare System. Participants were 18 years of age or older, English 
speaking, received outpatient obstetric care through Cleveland Clinic Healthcare 


















outpatient centers within Cleveland Clinic Healthcare System between May and July 
2020. This is a major healthcare system in Cleveland, Ohio which has over 13,000 
deliveries annually. We selected this timeframe as it reflected the onset and first major 
wave of the pandemic in U.S. and Ohio (Figure 1). For reference, there were an 
average of 564 cases per day at the start of data collection in May, which doubled to 
roughly 1,270 cases per day at the end of data collection in July.8 During this time, 
telehealth was instituted across the healthcare system and, while encouraged, not 
required.  
 
Participants were contacted by means of a recruitment letter. The recruitment letter 
indicated if the women were interested in sharing their knowledge and opinions of 
decision-making surrounding prenatal testing in light of the COVID-19 pandemic, to 
contact the research team for participation. Recruitment was structured to seek input 
from two groups of women who represent patients at different significant time points in 
pregnancy. One group included women in the first trimester of pregnancy to capture 
prenatal care needs, preferences, and experiences at the onset of the pregnancy and 
prenatal care delivery (Group 1). A second group included women in the second 
trimester, who had already considered or undergone prenatal genetic screening or 
diagnostic testing at the time of the interview (Group 2). Recruitment was continued until 



















After an informed consent process, each participant participated in a telephone 
interview to maintain consistency with the healthcare system’s recommendations for 
social distancing and patient contact for research purposes at the onset of the 
pandemic. Interviews were conducted by a member of the research team using a 
structured interview guide containing questions about knowledge and perception of the 
COVID-19 pandemic and the impact on their prenatal care (Appendix A). Items specific 
to prenatal genetic testing inquired about participants' baseline perceptions of the 
benefits and limitations of screens and diagnostic tests and how they would weigh these 
risks and benefits against the potential risks of COVID-19 exposure by presenting for 
testing procedures. This guide was developed in conjunction with content experts in 
obstetrics, clinical genetics, medical decision-making, patient experience, and maternal-
fetal medicine. With the participants' permission, the interviews were audio-recorded for 
analysis.   
 
Analysis was approached as an iterative and progressive process of data immersion, 
coding, memoing, and theme identification, an inductive process consistent with 
Grounded Theory.9,10 We identified content domains and categories in transcripts to 
create a coding tree used to organize the data. A companion codebook was created to 
serve as a reference for the analysis. The transcripts were coded by two members of 
the team (RF and MP) using NVivo (version 12). The research team held weekly 
meetings to identify themes by reviewing data, coding, and analytic memos to resolve 
any coding disagreements. Themes identified were contextualized with information 





















We contacted 115 (1st trimester) and 139 (2nd trimester) patients for study 
participation. We recruited a total of 40 pregnant women to take part in the study: 20 in 
their first trimester (Group 1) and 20 in their second trimester (Group 2). (Table 1). The 
majority (36) had already undergone prenatal aneuploidy screening or intended to 
undergo prenatal aneuploidy screening during the pregnancy.  None of the participants 
had undergone prenatal diagnostic testing by the time the interview was conducted. 
Five participants had COVID-19 testing; all tests were negative.   
 
Qualitative analysis identified three primary themes: 1) the impact of COVID-19 on the 
decision to undergo prenatal genetic testing, 2) the impact of COVID-19 on the timing of 
prenatal genetic testing decisions, and 3) heightened anxiety with the decision to 
undergo prenatal genetic testing. The themes and selected quotes are presented below 
with data from participant Groups 1 and 2 designated as G1 and G2. Additional data are 
included in Table 2. 
  
The Impact of COVID on the Decision to Undergo Pren atal Genetic Testing 
 


















Overall, we found that the pandemic did not significantly alter most patients’ choice to 
undergo or defer prenatal genetic testing. Yet, it did impact how all participants 
considered the benefits and risks of testing and the emotional reactions they 
experienced in the process. Participants were aware of the possible risks of SARS-CoV-
2 exposure by presenting for testing and the uncertainties of COVID-19 for pregnant 
women and newborns. These were factors they weighted in their decision-making 
process. However, the concern for COVID-19 did not often take priority in decisions to 
seek testing. As one participant stated, “The reward greatly outweighed the risk” (G2-
10).  
 
Most participants viewed the benefits of learning about the fetus through prenatal 
genetic testing as greater than the risk of potential exposure to the virus in the process 
of undergoing testing. The reasons for those benefits fell into two broad categories.  For 
one group, the benefits of prenatal genetic testing remained unchanged despite the 
pandemic. These women sought information so that they could make the decisions they 
felt were most appropriate for the future child and their family. As described by this 
participant: 
“So, it [COVID-19] wasn’t a deterrent because I wanted to have the test done 
more than I worried about getting COVID or giving COVID to other people” (G2-
12). While participants were aware of the limited knowledge about COVID-19 for 
pregnant women and newborns, this uncertainty often did not sway decisions 
about presenting to a healthcare facility for prenatal genetic testing.  “I actually 


















want the test to be good, right? You want positive results. So, that definitely 
was… that’s something I would’ve felt no matter what, pandemic or no pandemic” 
(G2-18).  
 
For another group, prenatal genetic testing presented an additional benefit: a sense of 
greater reassurance during a time of great uncertainty caused by the pandemic. 
Uncertainties extended beyond the rapidly changing landscape of knowledge about 
COVID-19 for the general population and pregnant women in addition to emerging 
policies about infection control and management. The personal, financial, and social 
changes of the pandemic also raised profound questions about the kind of world their 
child would grow up in (particularly concerning caring for a child with a serious medical 
condition) and how they could best help prepare for those challenges during pregnancy. 
Among women who had already decided to undergo testing, this notion of reassurance 
further justified their choice to undergo testing while taking on the risks of possible 
exposure to the virus. Yet, for some, the need for additional reassurance during this 
time tipped the decision-making scales toward undergoing testing despite pre-COVID 
preferences to decline any form of screening or diagnostic testing. As described by a 
participant, “I do feel that it [the decision about prenatal genetic testing] would change 
because right now it’s such an uncertain time in the world and to be able to have 
options to be able to know what potentially could be happening with your child kind of 
eases you right now because it’s so scary what’s going on right now” (G1-17). For these 


















genetic testing helped to counter the uncertainties for self and family resulting from the 
pandemic.  
 
The decision to decline prenatal genetic testing during the pandemic 
Yet, for some, the pandemic presented too much of a threat. For these participants, the 
decision for testing was either delayed or deferred, even when it may have been seen 
as a value before the pandemic. As described by this participant who decided against 
testing during the pandemic, “If all of this [COVID-19] wasn’t going on, considering this 
is my first pregnancy and how I am, I probably would have went through with everything 
possible under the sun […]. But because it’s [COVID] going on, I just kind of was like, 
‘Do I really need this done? Do I want to go through with that and be back at another 
appointment?’ […] ‘No. I don’t really want to come back. I’ll just come back in a month. 
I’ll skip it.’” (G1-03).  
 
The Impact of COVID on the Timing of Prenatal Genet ic Testing  
 
The decision not to postpone prenatal genetic testing during the pandemic  
Participants provided important insight into if and how COVID-19 may influence the 
decisions regarding the timing of prenatal genetic tests. Overall, most participants 
discussed that they did not or would not have postponed testing during the pandemic. 


















abnormalities early as possible in the pregnancy, a factor that was not swayed by the 
pandemic. “I wouldn’t want to push it off till later. I would want to know right away if 
there was an issue” (G2-11). There were additional benefits to seeking prenatal genetic 
testing earlier in the pregnancy as opposed to later because of the challenges 
presented but COVID-19. For this participant, early testing afforded a greater 
opportunity plan for a child with a serious medical condition amidst the physical, 
financial, and social challenges posed by the pandemic: 
“In a time of uncertainly, if you’re going to have a complication or something 
that’s going to impact what you want to do going moving forward, it might just be 
easier to just know it like as soon as possible. […] If I were to find out earlier and 
if the test can tell me definitively that something is very wrong with my pregnancy 
to the point where it’s not going to be viable, I would rather know that and then 
not have to be going through a pandemic pregnant and then having to deal with 
that at a later date.” (G2-18).  
 
There was also the recognition that delaying testing may not be an effective strategy to 
avoid the threats posed by the pandemic. As described by this participant, “I felt like this 
pandemic was going to be unpredictable and was going to be a while for things to settle 
down anyways. I thought that the pregnancy weeks would come a lot faster than the 



















Participants were cognizant of the potential for pandemic-related delays to access 
healthcare, including accessing both the personnel and the healthcare facilities required 
for testing. One concern participants had was that, if they did not proceed with prenatal 
genetic testing when it was initially offered, they might not be able to access it later due 
to unanticipated COVID-19-related delays. This participant reflected on her experiences 
during the early pandemic, “With that [the pandemic] happening, my second ultrasound 
did get rescheduled. […] So I did have a concern that, if the COVID-19 protocols 
increased, that [testing] would be pushed back out of the timeframe it needed to happen 
in, just because of more craziness and chaos that was going on outside” (G2-07). This 
concern also applied to participants who had already initiated testing and sought follow 
up testing to evaluate an abnormal result, leaving them in limbo between learning of a 
potential issue and obtaining the information needed to make key prenatal care 
decisions until a later time in the pregnancy (particularly relevant for time-sensitive 
maternal-fetal interventions or termination) or after birth. “The elective appointments and 
surgeries were being canceled. There was [sic] less people [healthcare providers]. So, I 
felt like it was better to get it done more quickly” (G2-20).   
 
The decision to postpone prenatal genetic testing during the pandemic  
At the same time, some participants spoke of the intent or decision to postpone prenatal 
genetic testing. For some, this decision pertained to the status of the pandemic at the 
time of the available window for testing. This was a time with rapidly evolving 
information about COVID-19 in addition to shifting policies with respect to healthcare 


















participant, the factors occurring at the onset of the pandemic would have affected 
decisions about test timing: “I probably would have considered testing later, in the early 
spring when I was still more newly pregnant. I feel like that was right at the height of the 
pandemic, or at least it felt like it was. […] If the option for later had been there, I 
probably would have gone to it later” (G2-16). For others, the timing of testing was 
influenced by how they perceived the threat of COVID exposure when presenting for 
testing. “If I get let in the building and I think there’s a huge swarm of people in the lab, I 
think I would come back at a different time” (G1-13).  This was a factor that was 
influenced by participants' trust in the healthcare system to control infection exposure. It 
was also influenced by a sense of trust or distrust in the choices and actions of other 
patients who were in the healthcare facility at the same time to prevent COVID-19. 
 
Heightened Anxiety Associated with Prenatal Genetic  Testing  
Participants who sought prenatal genetic testing despite the concerns of COVID-19 
reported the anxiety they experienced in the process. Participants were conscious of the 
risk of exposure to the virus when presenting for testing. “I think, for me, it was more 
important to get my prenatal screenings done, but I was aware of the risk I was taking” 
(G2-23). For these women, the process of presenting for testing was a source of 
anxiety. As described by this participant, “I want to do what’s best for me. But, at the 
same time, my anxiety about being in a doctor’s office or being in a space where I know 
there are potentially sick people nearby. […] I didn't want to be there. It wasn't like, 'Oh, 
I feel so comfortable and so safe here. I want to take my time, whatever and whatever.' 


















there'" (G1-03).  However, many elected to proceed with their choice despite the 
potential concern and distress resulting from presenting for testing.   
 
For some participants, their concern was heightened due to the location where they had 
to present for testing. One concern pertained to being in a healthcare facility where 
many other patients were seeking care and the choices those patients may make 
concerning infection-prevention approaches (e.g., social distancing, wearing masks). As 
described by this participant, “I’m also not really thrilled about going to the lab just 
because I know that those are generally busier places and it’s harder to control the 
number of people” (G1-16). There was also concern about presenting for testing in a 
hospital setting where COVID-19 patients were being treated. “I want the safety and 
security of being in a building where you know it’s not a hospital like the outpatient 
setting. I just felt more comfortable with because there’s not a floor above me of COVID 
patients” (G2-20). 
 
Participants discussed another significant concern: fear and anxiety of being alone 
during the testing process. As a result of visitor restriction policies, many participants 
underwent ultrasound-based screening and diagnostic testing procedures without a 
partner or support person. This was a concern for women who wanted to share the 
experience of seeing the fetus with a partner. Yet, for many, the concerns pertained to 
the possibility of learning about a fetal abnormality or demise by themselves during 
periods when visitor restrictions were in place. As described by this participant, “The 


















nervous about the health of the fetus. I was more worried about finding out by myself” 
(G2-23).  For participants in this study, the fear of being alone was unexpected—




The COVID-19 pandemic has dramatically altered the delivery of prenatal care. While 
telehealth quickly replaced in-person prenatal care visits, the utilization of prenatal 
genetic screens or diagnostic tests continues to require patients to present to a medical 
facility in person. An effective COVID-responsive healthcare delivery model must 
ensure that patients can access accurate, timely, and patient-centered information 
about their testing options. In addition, for those patients who elect to proceed with 
screening or diagnostic testing, it is critical that patients feel that they can safely access 
those tests amidst evolving information about infection control policies.  However, a 
greater challenge is ensuring these resources are in place while continuing to overcome 
barriers to patients' informed decision-making about prenatal genetic testing observed 
prior to the pandemic.11,12  Given the importance of prenatal genetic testing in prenatal 
care delivery, this study examined whether and how patient concerns about COVID-19 
at the onset of the pandemic may impact access and utilization of prenatal genetic tests. 
 
Our study sheds light on two major factors that may interfere with patient’s ability to 


















tests during the pandemic. First, the study findings highlight the increased complexity of 
the prenatal genetic testing decision-making process during the pandemic. We found 
that during the pandemic, participants expanded the number of risks and benefits they 
weighed in the decision-making process, adding to the existing set of risks and 
limitations already associated with prenatal genetic testing. For instance, participants 
incorporated the possible risks of exposure to SARS-CoV-2 by presenting for testing to 
the decision-making process. The risk of COVID did not represent one single concern. 
Instead, COVID presented a series of additional risks and implications to consider. This 
included not just the risks of exposure for themselves and the pregnancy but, more 
significantly, the risks, implications, sense of culpability, and feelings of regret if their 
children and other adults in the family became ill as a result of the decision to present to 
the healthcare facility for testing. These risks, in addition to those associated with 
prenatal genetic testing, presented an array of different implications for the pregnancy 
and family.  
 
The decision-making process also entailed an expanded view of the potential benefits of 
prenatal genetic testing. Participants in this study sought prenatal genetic testing as a 
source of reassurance during the pregnancy, a finding consistent with other studies.13-15   
Yet, for participants in this study, there was a greater urgency for reassurance in 
response to the numerous medical, personal, financial, and social uncertainties caused 
by the pandemic, something that some felt could be gained from prenatal genetic 
testing.  In fact, some were interested in gaining as much genetic information about the 


















during this time. This reassurance was seen as an additional benefit that they 
incorporated into decision-making. For those who underwent testing, this consideration 
provided further justification for their decision. For others, this perceived benefit led to 
the decision for testing when they would not have considered it prior to the pandemic. 
Notably, there was no discussion of the uncertainties that can come with prenatal 
genetic testing. Yet, this is an important consideration in the decision-making process, 
particularly in the post-test setting when potentially unexpected or uninterpretable 
results may be received.16,17 This finding raises the question of how we can help 
patients balance the reassurance they seek during the pandemic with a realistic view of 
the questions that may not be answered by prenatal genetic tests or may arise in the 
testing process. 
 
Key drivers in the decision-making process were notions of responsibility and obligation 
to make choices about prenatal genetic testing during the pandemic that would best 
benefit a newborn and family. Other authors have observed this decision-making factor, 
a concept often referred to as the "Good Mother” which describes a self and society-
imposed sense of obligations for pregnant women to take on or avoid risks for the 
benefit of the child.18,19 Our study highlights that this factor and the pressure to “make 
the right decision” was further amplified during the pandemic when patients considered 
the risks and uncertainties that may come with the decision to utilize prenatal genetic 
tests, defer them to a later time in the pandemic, or decline testing altogether during the 



















A second major factor to impact the decision-making process was anxiety. It is 
recognized that increased levels of anxiety and distress can negatively affect the 
decision-making process, presenting challenges for obtaining medical information and 
processing it in a way that is consistent with one’s values and preferences.20,21 Studies 
have shown that pregnant patients frequently experience anxiety and uncertainty during 
prenatal genetic testing.13,22,23 Yet, the COVID-19 pandemic has provoked a series of 
other concerns for pregnant women considering prenatal genetic testing, sources of 
anxiety that have not been fully identified with past infectious disease threats.24,25 As 
described above, the pressure to make “the right decision” weighed heavily on 
participants. In addition, there was concern about the ability to access the healthcare 
system and tests in a timely manner due to both disruptions in healthcare provision and 
the feeling of trust and safety in the clinical environment. As the COVID-19 pandemic 
has led to unprecedented changes in healthcare delivery, it is not possible to compare 
these concerns with pregnant patients' experiences considering other infectious threats. 
Yet, the sequelae of delays and barriers to prenatal care and prenatal genetic tests are 
well-documented apart from the pandemic.5 Such issues are particularly significant 
among those who already face barriers to early prenatal care,6 raising the concern of 
further exacerbation of inequities and healthcare disparities resulting from COVID-19.26, 
27  Given these concerns, it is critical to ensure that preventable delays to patients' 
access prenatal genetic test access are avoided. 
 
Another source of anxiety was noted: the fear of being alone and without their partner or 


















participants found themselves undergoing an ultrasound-based procedure without their 
partner as a result of visitor restriction policies. For many, this was an unexpected 
feeling, something that they did not realize until the testing procedure was taking place. 
This is significant for several reasons. Studies show that many pregnant women elect to 
include a partner or other support person in the prenatal genetic testing process and 
several other aspects of prenatal care, a finding also noted among our participants.28-31 
There are emerging data during the pandemic about the impact of separation of a 
pregnant woman from her partner during labor and delivery,32,33 in addition to data 
about patients’ decision-making during COVID-19 when separated from their families at 
the time of acute medical decision.29,34 While such research is ongoing, our study 
demonstrates that it is also important to investigate the impact of isolation at the time of 
prenatal genetic testing procedures for pregnant women and their families.   
 
These findings of increased decision-making complexity and associated anxiety 
highlight the need for further research focused on ensuring that patients can make 
informed, value-reflective decisions during the current pandemic and future similar 
public health emergencies. While this study sheds light on patient and healthcare-based 
factors that impact access to prenatal genetic tests, other important changes have taken 
place at the level of healthcare systems and policy that are not reflected in our findings 
and may also further complicate the informed decision-making process. For instance, 
some insurers have changed their coverage benefits or pre-authorization requirements 
for cell free fetal DNA screening in response to COVID.35-37 As a result, a subset of 


















which they may not have considered prior to presenting for prenatal care. While such 
changes will expand access during the pandemic, they also raise additional questions 
about how to best prepare patients for changing prenatal genetic testing options amidst 
the pandemic and future public health emergencies that cause major disruptions in the 
lives of patients and society.  
 
As a first step, it is important to recognize factors resulting from the pandemic that may 
interfere with pregnant patients' ability to make informed decisions about their testing 
options. This recognition will pave the way to develop infrastructure and tools to support 
patients' decision-making during the pandemic. Such resources may include identifying 
members of the healthcare team who can follow up with patients after the visit, help 
answer questions, and support the shared decision-making process. This follow up 
could also include a mechanism to assess patients’ anxiety in the interval between the 
clinical encounter, particularly around seeking prenatal care and prenatal genetic testing 
during the pandemic. Given the emerging data regarding increased levels of 
psychological distress among pregnant women as a result of COVID-1938,39 and the 
evidence of the implications of anxiety and mental health on prenatal and postpartum 
outcomes,22,23,40 it is critical to mitigate the impact of compounded stressors that could 
impact decisions, test-associated decisional satisfaction, and obstetric outcomes during 



















While this study provides insight into the impact of COVID-19 on patients’ prenatal 
genetic testing decision-making, there are limitations to consider. We utilized qualitative 
methods to identify emergent themes among a sample of patients at a single healthcare 
system. Thus, our sample size is limited, as is the racial and ethnic representation 
among the sample population. Our sample may not have included women's 
perspectives who may have elected not to present for prenatal care during the 
pandemic. Further qualitative and quantitative research is needed to continue to explore 
the factors that may impact patients’ access to prenatal care and prenatal genetic 
testing during this time.  
 
CONCLUSION  
 Our study sheds light on the impact of COVID-19 on patients' decision-making needs 
and preferences during the uncertainty of the pandemic. These findings demonstrate 
the need for effective tools and strategies to ensure that patients' informed access to 
prenatal genetic tests is not impaired by the pandemic. This is signficant as such 
barriers that emerge during the time period of the pandemic may have a long-term 
indelible impact on women, their families, and their future family-building decisions. As a 
next step, it is critical to further understand the nature, extent, and impact of COVID-19 
on women's ability to access prenatal genetic tests in a timely and informed manner, 
with implications not just for patient care during the current pandemic and future public 
























Data Availability Statement:  The data that support the findings of this study are 
available on request from the corresponding author. The data are not publicly available 
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Table 1: Demographics 
Demographics of Participants Total (n=40) 
Age 32.25 ± 4.54 
Non-AMA (<35) 27 (67.5%) 
AMA (≥35) 13 (32.5%) 
Race 
White 34 (85.0%) 
Black 4 (10%) 
Asian 2 (5.0%) 
Reproductive History 
Primigradiva 15 (37.5%) 
Multigradiva 25 (62.5%) 
Trimester of pregnancy 
1st trimester  20 (50%) 
2nd trimester  20 (50%) 
Prenatal genetic screening or diagnostic testing  
        Undergone  screening or diagnostic  
        testing  
36 (90.0%) 



















Table 2: Additional Qualitative Data  
Theme Illustrative Quotes 
The Impact of COVID 




“I think me finding out what’s wrong is more beneficial than 
thinking about coronavirus. Yeah, there is a risk.” (G1-08)  
 
“Above all … the health of my child … I think about the 
health of my child a little bit more than my health with a lot 
of things. So I figured this was something that was 
recommended for me to get done. I just wanted to get it 
done and make sure everything was okay with him. So, I 
felt as long as I was taking all the precautions, I could take 
to get the testing done  and people around me were taking 
those precautions as well, and I wasn’t touching my face 
and I was washing my hands, I felt okay going to get them 
done.”(G2-16) 
 
“Being prepared if anything was off … especially in the 
current climate of things going wrong. Cause (sic) it kind of 
feels like everything that can go wrong is going wrong right 
now and just having the mindset of being prepared and 
knowing.” (G2-02) 
The Impact of COVID 




“I think I would want to have it done when I need to have it 
done. It’s normally done at a certain week and if I am at 
that point and have orders to do it, I would do it. The 
coronavirus won’t stop me from doing it, you know. ” (G1-
08).   
 
“I wasn’t going to do anything with the results [referring to 
the prior pregnancy]. I wasn’t going to terminate the 


















previous pregnancies. In this pregnancy, I’m older. Things 
are going on with the world. So, I was looking for that 
reassurance.” (G1-13) 
 
“If I get let in the building and I think there’s a huge swam 
of people in the lab, I think I would come back at a different 
time” (G1-13).    
 
“I don’t know what I would do. I don’t know if I would 
terminate the pregnancy, but that is an option that you 
would have early on rather than later” (G1-02). 
 
Heightened Anxiety 
Associated with The 




“I think it is a more high anxiety thing. […] So going 
anywhere is stressful, especially where there is sick 
people. So I guess when I have to go anywhere, whether it 
is for the genetic testing or not, I don’t think that is a 
deterrent for me having to go to the hospital and 
considering if I was going to have the genetic testing […] , 
or to go to the hospital to have testing done.  There is 
definitely a level of stress that comes along with that” (G1-
02)  
 
“I’m putting myself into a setting that medically maybe it 
wouldn’t be ideal to go into if you didn’t have to right now” 
(G2-18) 
 
“When I went for my 20 week anatomy scan, while I was 
waiting for the doctor to come in, I had a little moment of 
panic like, ‘What if something is wrong and I am by 
myself? I have to hear this information by myself?’ That 


















Figure 1: Trends in COVID cases during the study timeline  
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